Abraxane: Side Effects & Dosing

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Paclitaxel

Indications/Uses

Monotherapy for metastatic breast cancer in adult patients who have failed 1st-line treatment for metastatic disease & for whom standard, anthracycline containing therapy is not indicated. In combination w/ gemcitabine for the 1st-line treatment of adult patients w/ metastatic pancreas adenocarcinoma. In combination w/ carboplatin as 1st-line treatment of locally advanced or metastatic NSCLC in patients who are not candidates for curative surgery or RT.

Dosage/Direction for Use

IV Breast cancer 260 mg/m² over 30 mins every 3 wk. Patient who experiences severe neutropenia (neutrophil count <500 cells/mm³ for ≥1 wk) or sensory neuropathy during therapy Reduce dose to 220 mg/m² for subsequent courses. In following recurrence, further reduce dose to 180 mg/m². Pancreatic adenocarcinoma Paclitaxel: 125 mg/m² over 30 min on days 1, 8 & 15 of each 28-day cycle. Gemcitabine: 1,000 mg/m² over 30 min immediately after completion of Abraxane administration on days 1, 8 & 15 of each 28-day cycle. NSCLC 100 mg/m² infusion over 30 min on days 1, 8 & 15 of each 21-day cycle. Administer carboplatin on day 1 of each 21-day cycle immediately after Abraxane.

Contraindications

Hypersensitivity. Patients who have baseline neutrophil counts <1,500 cells/mm³. Lactation.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01CD01 - paclitaxel ; Belongs to the class of taxanes from plant alkaloids and other natural products. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Abraxane powd for inj 100 mg

Packing/Price

1's

Abraxane

paclitaxel

Manufacturer:

Baxter Oncology GmbH